| Course | NUR 635 Advanced Pharmacology |
|---|---|
| Topic | Topic 3 |
| Paper type | Cardiovascular prescribing analysis |
| Length | About 970 words, 4 pages |
| Format | APA 7 student paper |
| School | Grand Canyon University (GCU) |
| Program | MSN |
| Updated | October 2026 |
Free sample paper for NUR 635 Topic 3
Adding Diltiazem to Eight Other Things: A Cardiovascular Prescribing Analysis for Rate Control in a 69-Year-Old Woman With Atrial Fibrillation
[Author Name]
College of Nursing and Health Care Professions, Grand Canyon University
NUR-635: Advanced Pharmacology
Topic 3 Assignment
[Instructor Name]
January 28, 2030
The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.
Adding Diltiazem to Eight Other Things: A Cardiovascular Prescribing Analysis for Rate Control in a 69-Year-Old Woman With Atrial Fibrillation
The Indication and the Patient
Mrs. C., a composite 69-year-old woman weighing 64 kg, has persistent atrial fibrillation with a resting ventricular rate of 118 per minute despite metoprolol succinate 100 mg daily, and she is breathless climbing stairs. Echocardiography shows a left ventricular ejection fraction of 55 percent, so she does not have heart failure with reduced ejection fraction. Kidney function is mildly reduced, with a creatinine of 1.1 mg/dL and an estimated filtration rate of 52; potassium 4.3 mmol/L and blood pressure 138/84 mm Hg. The goal is a resting rate below 110 per minute with relief of symptoms; a lenient target of this kind was not inferior to strict control below 80 per minute in a randomized trial of patients with permanent atrial fibrillation (Van Gelder et al., 2010).
Everything She Takes
The list below was built from her pharmacy record and from the bag of bottles she brought, and it includes what she buys herself.
Table 1
Mrs. C.'s Current Medications
| Medication | Dose | Source |
|---|---|---|
| Apixaban | 5 mg twice daily | Prescribed |
| Metoprolol succinate | 100 mg daily | Prescribed |
| Simvastatin | 40 mg nightly | Prescribed |
| Lisinopril | 10 mg daily | Prescribed |
| Omeprazole | 20 mg daily | Bought without a prescription |
| Ibuprofen | 400 mg on most weekends and after gardening, for knee pain | Bought without a prescription |
| St. John's wort | 300 mg three times daily, started two months ago for low mood | Supplement |
| Turmeric capsules | 500 mg daily | Supplement |
The Proposed Agent and Why It Fits
The proposal is diltiazem extended-release, 120 mg daily, titrated to 180 mg if needed. A nondihydropyridine calcium channel blocker slows conduction through the atrioventricular node, adding to the beta blocker's effect. It suits her because her ejection fraction is preserved; in reduced ejection fraction, diltiazem's negative inotropic effect would make it unsafe. Increasing metoprolol was considered first and declined because she already reports fatigue at 100 mg. Digoxin was declined because it controls the rate poorly during exertion, which is when she is symptomatic, and her reduced kidney function would require close level monitoring.
Interactions, Each With Its Mechanism and a Decision
Simvastatin and diltiazem: diltiazem is a moderate inhibitor of cytochrome P450 3A4, the enzyme that metabolizes simvastatin, so simvastatin concentrations rise and the risk of myopathy and rhabdomyolysis rises with them. Current recommendations limit simvastatin to 10 mg daily with diltiazem (Wiggins et al., 2016). Decision: avoid the combination at her current dose. Simvastatin is replaced with rosuvastatin 10 mg, which does not depend on that enzyme.
Metoprolol and diltiazem: an additive pharmacodynamic effect on the atrioventricular node and on heart rate, with a risk of bradycardia and heart block. This is the intended effect in moderation. Decision: permit under monitoring, starting diltiazem at the lowest dose.
Apixaban and diltiazem: diltiazem moderately inhibits both the enzyme and the P-glycoprotein transporter that clear apixaban, raising its concentration modestly. No dose change is required, but bleeding risk rises slightly. Decision: permit and monitor. Her apixaban dose stays at 5 mg because she meets none of the criteria for the reduced dose, age 80 or over, weight 60 kg or less, creatinine 1.5 mg/dL or more.
Apixaban and St. John's wort: the most dangerous interaction on the list runs in the opposite direction from the others, because St. John's wort induces both the enzyme and the transporter, lowering apixaban concentrations and with them her protection against stroke, and it would also lower diltiazem concentrations and blunt the new drug's effect. Induction by St. John's wort is among the best documented herb-drug interactions (Izzo, 2012). Decision: avoid. She will stop it, and her low mood will be assessed properly at a separate visit, since the supplement was treating a problem that still needs attention.
Apixaban and ibuprofen: additive bleeding risk, because the anti-inflammatory drug impairs platelet function and injures the stomach lining; with lisinopril, ibuprofen also reduces kidney blood flow. Decision: avoid. Knee pain will be managed with acetaminophen up to 3 g a day and topical diclofenac. Turmeric has weak evidence of antiplatelet effects; she is advised to stop it while taking an anticoagulant. Omeprazole has no important interaction with diltiazem and may reduce gastrointestinal bleeding risk while she takes an anticoagulant, so it continues, now recorded on her prescribed list rather than left as a store purchase.
Monitoring, With Thresholds
Heart rate and blood pressure will be checked at one week and after each dose change. If her resting rate stays at or above 110, diltiazem increases to 180 mg. If her resting rate falls below 55, or systolic pressure below 100 mm Hg with dizziness, the dose is reduced. An electrocardiogram at one week checks the PR interval; a PR interval above 250 ms or any second-degree block would prompt a dose reduction or a change of strategy. A lipid panel at 8 weeks checks that rosuvastatin is achieving the same effect, and creatine kinase is measured only if she reports muscle pain. Hemoglobin and kidney function are checked at one month. She will record home pulse readings each morning.
What She Was Told to Watch For
Mrs. C. was told to call the clinic the same day if her home pulse is below 50, if she feels faint or blacks out, if she notices unexplained muscle pain or dark urine, or if her ankles swell markedly, a common effect of diltiazem. She was told to go to the emergency department for black stools, vomiting blood, a severe headache or any sign of stroke. She was asked to bring every bottle, including anything bought in a store, to each visit, and not to start a supplement without asking first. She agreed to stop St. John's wort, turmeric and ibuprofen today, and a mood visit is booked for next week.
References
Izzo, A. A. (2012). Interactions between herbs and conventional drugs: Overview of the clinical data. Medical Principles and Practice, 21(5), 404-428. https://doi.org/10.1159/000334488
Van Gelder, I. C., Groenveld, H. F., Crijns, H. J. G. M., Tuininga, Y. S., Tijssen, J. G. P., Alings, A. M., Hillege, H. L., Bergsma-Kadijk, J. A., Cornel, J. H., Kamp, O., Tukkie, R., Bosker, H. A., Van Veldhuisen, D. J., & Van den Berg, M. P. (2010). Lenient versus strict rate control in patients with atrial fibrillation. New England Journal of Medicine, 362(15), 1363-1373. https://doi.org/10.1056/NEJMoa1001337
Wiggins, B. S., Saseen, J. J., Page, R. L., Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D., Virani, S., & Morris, P. B. (2016). Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: A scientific statement from the American Heart Association. Circulation, 134(21), e468-e495. https://doi.org/10.1161/CIR.0000000000000456
The NUR-635 Topic 3 assignment instructions
Topic 3 in NUR-635 asks students to analyze a cardiovascular prescribing decision in a patient taking several medicines. Strong papers state the indication and the target, build a complete list that includes over-the-counter products and supplements, and explain why the proposed agent fits this patient rather than the condition in general. Students should report the interactions that matter, each with its mechanism and a decision, such as lowering a statin dose, rather than reproducing an interaction checker. The analysis should finish with monitoring that names parameters, timing and thresholds for action, and with the warning signs the patient was told to watch for. A dose and a titration step should both be stated, with what result would prompt the next step.
How this NUR 635 Topic 3 example is built
The finished example reviews before it prescribes. The patient's existing medications are listed in full, including anything obtained without a prescription and any supplement, since several of the clinically important interactions in this group come from exactly those. Each potential interaction is then named with its mechanism rather than flagged, so a reader learns whether the problem is a metabolic pathway, an additive effect on rate or pressure, or an electrolyte consequence, and can judge how much it matters. The example distinguishes interactions requiring avoidance from those requiring monitoring, which is the judgment students most often skip. Monitoring is then specified with what is measured, when, and what result would prompt a change.
Reading the NUR 635 Topic 3 rubric
Faculty reward interactions reported with mechanisms and decisions. An Excellent analysis states the indication and a lenient rate target from Van Gelder and colleagues, then lists every product, including supplements weighed with Izzo. Credit goes to explaining why diltiazem extended-release fits. The rubric values limiting simvastatin to 10 mg because diltiazem inhibits CYP3A4, citing Wiggins and colleagues. Strong papers set monitoring with thresholds, such as raising the dose if the rate stays at 110 or more. Top marks go to warning signs written as the patient heard them.
NUR 635 Topic 3 help: mistakes that cost marks
Recommendations made without reviewing the existing list are the central failure here, because the interaction risk in this drug group is high enough that an unchecked addition is unsafe rather than merely incomplete. A second weakness is interactions flagged without mechanisms, which leaves a reader unable to judge severity or to reason about a substitute. Papers lose marks for treating every interaction as prohibitive, since most permit the combination with monitoring and blanket avoidance is its own clinical error. Monitoring described as routine follow up specifies nothing. Omitting renal function where the agent requires adjustment is the safety error faculty look for first in this topic. Interaction lists reproduced wholesale from a checker demonstrate a search rather than a judgment.
Get an NUR-635 Topic 3 example written to your instructions
Send the NUR-635 Topic 3 instructions and the rubric your classroom posts, with the patient, the indication and the current medication list. We write a custom example to those criteria, with every interaction given a mechanism and a severity, avoidance separated from monitoring and thresholds attached to each parameter, in 24 to 48 hours. The first is free.
More NUR 635 papers and MSN samples
- NUR 635 Topic 1: Pharmacokinetics Application
- NUR 635 Topic 2: Antimicrobial Selection Rationale
- NUR 635 Topic 4: Respiratory Therapy Plan
- NUR 635 Topic 5: Apixaban Drug Selection Paper
- NUR 635 Topic 6: Risk Benefit Prescribing Analysis
- NUR 635 Topic 7: Special Population Dosing
- NUR 635 Topic 8: Comprehensive Prescribing Case
- NUR 641EA Topic 3: Confusable Drug Class Contrast
- NUR 634 Topic 3: Cardiac Examination Note
- NUR 643EA Topic 3: Documentation for the Next Clinician
- NUR 631 Topic 3: Prerenal AKI Mechanism Analysis
NUR 635 Topic 3 questions, answered
Do I have to check every possible interaction?
Check systematically and report the ones that matter. An interaction checker will return a long list including many of no clinical consequence, and reproducing it demonstrates nothing. What earns marks is triage: which interactions are clinically significant for this patient given their renal function, their other conditions and the doses involved, and what you would do about each. Judgment is the assessed skill.
Why do supplements need to be on the list?
Because several affect cardiovascular drugs substantially and patients frequently do not mention them, since they are not thought of as medicines. Products affecting clotting, potassium, or hepatic enzyme activity can change the safety of a prescription without appearing anywhere in the record. Asking specifically, and recording the answer, is part of the review rather than an optional extra.
What makes a monitoring plan adequate?
Named parameters, stated timing and a threshold for action. Check renal function and potassium in one to two weeks, and reduce or stop if potassium exceeds a stated value, is a plan. Monitor closely is not, because it tells the next clinician nothing about what to measure or when to act. The threshold is the part students most often leave out.
Where can I find a free NUR 635 Topic 3 sample paper?
The analysis for NUR 635 Topic 3 covers the indication and patient, the complete medication list, the proposed agent, interactions with mechanisms and decisions, monitoring with thresholds and the warning signs given. Post your NUR 635 Topic 3 prompt and get a free paper.
Why lower the simvastatin dose rather than stop diltiazem in NUR 635 Topic 3?
Because diltiazem is the agent chosen for rate control and the interaction has a known ceiling: simvastatin at 10 mg daily or less keeps the myopathy risk acceptable while both continue.